Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?
Related Questions
Would you continue zolendronic acid infusions if the bone density decreases significantly in year two?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
What treatment would you consider for severe osteoporosis in a patient with multiple fractures, AVN of jaw from denosumab, history of stroke and who has completed a PTH analog?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?
Would you consider teriparatide use in a patient with prior radiation therapy, given that the black box warning regarding osteosarcoma risk has been removed by the FDA?
Have the results of the ancillary study of the VITAL trial, demonstrating that Vitamin D3 supplementation did not reduce the incident rate of fractures in generally healthy midlife and older adults, changed how you prescribe Vitamin D?
Can romosozumab be used in patients on dialysis?
What do you consider as absolute and relative contraindications for the use of romosozumab?
